CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.96
−3.16%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.00
From 52W high−61.80%
Volume1.72M
Market cap$148.12M
P/E (TTM)—
P/S (TTM)2.9x
Div yield—
Key dataOct 19, 2026
Open
$1.00
From 52W high
−61.80%
Volume
1.72M
Market cap
$148.12M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
35.0
MomentumView details →
1D Return
−3.16%
YTD Return
−30.85%
SummaryUpdated Jun 1, 2026
Coherus BioSciences, Inc. (NASDAQ:CHRS) is a biopharmaceutical company founded in 2010 and headquartered in Redwood City, California. Originally established as BioGenerics, Inc., the company changed its name to Coherus BioSciences in April 2012 and went public in November 2014. The company has undergone a significant strategic transformation, evolving from a biosimilar-focused business to an innovative oncology company. Following the divestiture of its biosimilar assets in 2024-2025, Coherus now concentrates exclusively on developing and commercializing novel cancer treatments, particularly focusing on immuno-oncology therapies that target the tumor microenvironment.
Similar companies
Latest newsMore news →